MBX Biosciences, Inc. - 10-Q Filing

MBX Biosciences reports third quarter 2026 financial results including updates on R&D expenses and equity incentive plan activity.

SEC EDGAR ·

Tickers: $MBX

Read the full article at SEC EDGAR

More Regulatory news